Drug Profile
RG 101
Alternative Names: RG-101; RG-101RxLatest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator Stanford University
- Developer Regulus Therapeutics
- Class Antisense oligonucleotides; Antivirals; MicroRNAs
- Mechanism of Action MIRN122 microRNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 08 Sep 2021 Regulus and GlaxoSmithKline completed a phase II trial in chronic Hepatitis C
- 01 Aug 2017 Discontinued - Phase-I for Hepatitis C in USA, Netherlands (SC) before August 2017
- 01 Aug 2017 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in Spain, Greece, Hungary (SC) before August 2017